This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Coustan-Smith E, Mullighan CG, Onciu M, Behm FG, Raimondi SC, Pei D et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol 2009; 10: 147–156.
Bell JJ, Bhandoola A . The earliest thymic progenitors for T cells possess myeloid lineage potential. Nature 2008; 452: 764–767.
Balgobind BV, Van Vlierberghe P, van den Ouweland AM, Beverloo HB, Terlouw-Kromosoeto JN, van Wering ER et al. Leukemia-associated NF1 inactivation in patients with pediatric T-ALL and AML lacking evidence for neurofibromatosis. Blood 2008; 111: 4322–4328.
Martinelli G, Iacobucci I, Paolini S, Ottaviani E . Farnesyltransferase inhibition in hematologic malignancies: the clinical experience with tipifarnib. Clin Adv Hematol Oncol 2008; 6: 303–310.
Brandwein JM, Leber BF, Howson-Jan K, Schimmer AD, Schuh AC, Gupta V et al. A phase I study of tipifarnib combined with conventional induction and consolidation therapy for previously untreated patients with acute myeloid leukemia aged 60 years and over. Leukemia 2009; 23: 631–634.
Goemans BF, Zwaan CM, Harlow A, Loonen AH, Gibson BE, Hählen K et al. In vitro profiling of the sensitivity of pediatric leukemia cells to tipifarnib: identification of T-cell ALL and FAB M5 AML as the most sensitive subsets. Blood 2005; 106: 3532–3537.
Widemann BC, Salzer WL, Arceci RJ, Blaney SM, Fox E, End D et al. Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas. J Clin Oncol 2006; 24: 507–516.
Raponi M, Lancet JE, Fan H, Dossey L, Lee G, Gojo I et al. A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia. Blood 2008; 111: 2589–2596.
Acknowledgements
We thank the Association ‘Morgan di Gianvittorio’ for funding and Ageop for support.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies the paper on the Leukemia website
Supplementary information
Rights and permissions
About this article
Cite this article
Biagi, C., Astolfi, A., Masetti, R. et al. Pediatric early T-cell precursor leukemia with NF1 deletion and high-sensitivity in vitro to tipifarnib. Leukemia 24, 1230–1233 (2010). https://doi.org/10.1038/leu.2010.81
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2010.81
This article is cited by
-
AMP-dependent kinase/mammalian target of rapamycin complex 1 signaling in T-cell acute lymphoblastic leukemia: therapeutic implications
Leukemia (2012)
-
Tipifarnib-mediated suppression of T-bet-dependent signaling pathways
Cancer Immunology, Immunotherapy (2012)